Table 2. Treatment and outcome of 37 cases of sporotrichosis in the nasal mucosa, according to clinical form, treated at the ENT outpatient clinic of the INI/FIOCRUZ (1998–2020).
| Case | Clinical form | Other sites | Medication | Time of treatment (in weeks)1 | Outcome |
|---|---|---|---|---|---|
| 1 | Disseminated2 | Skin (multiple), larynx, bone (femur) | Antifungal combination3 | 65 | Under treatment |
| 2 | Disseminated | Skin (multiple), lip, bone (tibia & fibula) | Itraconazole 200 mg | 133 | Cure |
| 3 | Disseminated | Skin (multiple) | Antifungal combination | 114 | Cure |
| 4 | Disseminated | Skin (multiple) | Antifungal combination | 238 | Loss of follow-up |
| 5 | Disseminated | Skin (multiple) | Itraconazole 200 mg | 203 | Under treatment |
| 6 | Localized | NA | Antifungal combination | 40 | Cure |
| 7 | Localized | NA | Itraconazole 100 mg | 16 | Cure |
| 8 | Disseminated | Skin (nose), CNS, bone (hand, radio, ulna) | Antifungal combination | 114 | Death |
| 9 | Localized | NA | Itraconazole 100 mg | 34 | Cure |
| 10 | Disseminated | Skin, lymph node, bone (multiple) | Antifungal combination | 298 | Loss of follow-up |
| 11 | Disseminated | Skin (multiple), oral mucosa | Antifungal combination | 150 | Cure |
| 12 | Disseminated | Skin (multiple), bone (L hand) | Antifungal combination | 100 | Loss of follow-up |
| 13 | Disseminated | Skin (multiple) | Antifungal combination | 65 | Cure |
| 14 | Disseminated | Skin (multiple), oral mucosa, eye, bone (multiple) | Antifungal combination | 173 | Death |
| 15 | Localized | NA | Itraconazole 200 mg | 21 | Cure |
| 16 | Disseminated | Skin (multiple), oral mucosa, bone (hands) | Antifungal combination | 65 | Cure |
| 17 | Localized | NA | Antifungal combination | 13 | Cure |
| 18 | Disseminated | Skin (multiple) | Antifungal combination | 61 | Cure |
| 19 | Localized | NA | Antifungal combination | 17 | Cure |
| 20 | Disseminated | Skin (multiple), bone (multiple) | Antifungal combination | 458 | Loss of follow-up |
| 21 | Disseminated | Skin (multiple), oropharynx, eye, bone (multiple), blood | Antifungal combination | 374 | Loss of follow-up |
| 22 | Disseminated | Skin (hand) | Itraconazole 100 mg | 18 | Cure |
| 23 | Localized | NA | Antifungal combination | 30 | Cure |
| 24 | Disseminated | Skin (toe) | Antifungal combination | 76 | Loss of follow-up |
| 25 | Localized | NA | Itraconazole 100 mg | 14 | Cure |
| 26 | Localized | NA | Itraconazole 100 mg | 1 | Loss of follow-up |
| 27 | Disseminated | Skin, oropharyngeal, and genital mucosa, synovia, bone (L foot, R knee) | Antifungal combination | 574 | Cure |
| 28 | Disseminated | Skin (multiple) | Antifungal combination | 187 | Loss of follow-up |
| 29 | Localized | NA | Itraconazole 100 mg | 67 | Cure |
| 30 | Disseminated | Skin (L ear) | Itraconazole 100 mg | 25 | Cure |
| 31 | Disseminated | Skin (R thumb, BLE), eye | Itraconazole 100 mg | 20 | Cure |
| 32 | Disseminated | Skin, oral mucosa, bone (multiple) | Antifungal combination | 265 | Cure |
| 33 | Disseminated | Oral mucosa | Antifungal combination | 95 | Cure |
| 34 | Localized | NA | Antifungal combination | 115 | Cure |
| 35 | Localized | NA | Itraconazole 100 mg | 11 | Cure |
| 36 | Localized | NA | Itraconazole 100 mg | 26 | Cure |
| 37 | Localized | NA | Itraconazole 100 mg | 9 | Loss of follow-up |
NA: not applicable. CNS: central nervous system. L: left. R: right. BLE: both lower extremities. 1Period from the start to the end of medication. 2The disseminated and disseminated cutaneous sporotrichosis forms were considered as disseminated. 3Antifungal combination: itraconazole 100–400 mg/day combined with amphotericin B and/or terbinafine. Source: Electronic patient data system and Laboratory of Mycology database, both from INI/FIOCRUZ.